Santen to buy Merck’s ophthalmology products
The products include COSOPT, COSOPT PF, TRUSOPT, TRUSOPT PF, TIMOPTIC, TIMOPTIC PF, TIMOPTIC XE, SAFLUTAN and TAPTIQOM. The company said that annual sales of these ophthalmology products in

The products include COSOPT, COSOPT PF, TRUSOPT, TRUSOPT PF, TIMOPTIC, TIMOPTIC PF, TIMOPTIC XE, SAFLUTAN and TAPTIQOM. The company said that annual sales of these ophthalmology products in

EoE is a recently recognized allergic inflammatory disease, characterized by swelling of the esophagus and its symptoms include vomiting, abdominal pain, regurgitation and dysphagia. Due to the diverse

The approval is for doses 8mg, 12mg and 16mg of Exalgo (Hydromorphone Hydrochloride Extended-release Tablets). The drug is indicated for the management of moderate to severe pain in

The company said that without treatment, the symptoms of schizoaffective disorder are complex and disabling. At present, there are limited treatment options approved for managing the symptoms of

The deal is aimed at developing new drugs that can benefit the large population of people with unmet needs in the pain management area. Under the deal, Jubilant’s

The ANDA involved contributions from both Perrigo and Impax Laboratories, who will share certain costs and benefits of Astepro Nasal Spray. The spray is a prescription medicine for

Under the deal signed by Seoul National University’s College of Pharmacy and Agilent, the partnership is aimed at carrying out drug metabolism studies; research, evaluate and develop new

Acanya (clindamycin phosphate and benzoyl peroxide) Gel is a lincosamide antibiotic and benzoyl peroxide indicated for the topical treatment of acne vulgaris. As part of the deal, Valeant

The company entered into an agreement for the lease of the comprehensive facility, which will allow it to carry out research as well as manufacture microspheres for its

Under the deal, Berg’s Interrogative Biology platform will be applied to several serum, urine, and kidney data points from select individuals, both lupus patients and controls followed in